5 of Last Week's Biggest Winners
What's better than momentum? Mo' momentum.
Let's take a closer look at five of this past week's biggest scorchers.
Company | Sep. 21 | Weekly Gain | My Watchlist |
|---|---|---|---|
IRIS International (NAS: IRIS) | $19.47 | 45% | |
Acadia Pharmaceuticals (NAS: ACAD) | $2.62 | 24% | |
NII Holdings (NAS: NIHD) | $8.34 | 24% | |
Complete Genomics (NAS: GNOM) | $3.09 | 16% | |
Nanosphere (NAS: NSPH) | $3.79 | 15% |
Source: Barron's.
IRIS soared last week after receiving a buyout offer. Shareholders of the medical diagnostics provider will be cashed out at $19.50 a share in a tender offer.
Acadia Pharmaceuticals had a strong midweek run. Top-line results for the critical phase 3 study of a promising drug to treat Parkinson's-related psychosis are expected by the end of November. Expect plenty of volatile trading in the coming weeks as the company reaches that important revelation.
NII Holdings made a winning connection after CEO Steve Dussek increased his stake in the company, by 12%. It's a strong show of confidence for the Latin American wireless service provider.
Complete Genomics notched most of last week's gains on Monday, after the gene-sequencing specialist revealed that it would be acquired by China's BGI-Shenzhen. Complete Genomics had put itself up for sale when it initiated a strategic review earlier this year.
Nanosphere gained ground after the TheStreet.com published a bullish article on the provider of advanced molecular diagnostics systems. The shares also got a continued boost on Friday morning after announcing that its CFO would be speaking at an investor conference.
More winners for you
It was a great week for these five stocks. If you want to get an early read on some of tomorrow's major gainers there's a special report on three hidden winners in a booming industry. The report is free -- like this article -- but it won't be around forever, so check it out now.
The article 5 of Last Week's Biggest Winners originally appeared on Fool.com.
The Motley Fool has adisclosure policy. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. Try any of our Foolish newsletter servicesfree for 30 days.Longtime Fool contributorRick Munarrizcalls them as he sees them. He does not own shares in any of the stocks in this story. Rick is also part of theRule Breakersnewsletter research team, seeking out tomorrow's ultimate growth stocks a day early.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
